• 1
    Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The dionysos study group. Gut 1997; 41: 84550.
  • 2
    Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 110610.
  • 3
    Dixon J B, Bhathal P S, O'Brian P E. Non-alcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91100.
  • 4
    Stewart S F, Jones D E J, Day C P. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 2001; 7: 40813.
  • 5
    Day C P. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 66378.
  • 6
    Day C P. From fat to inflammation. Gastroenterology 2006; 130: 20710.
  • 7
    Stewart S F, Vidali M, Day C P, Albano E, Jones D E J. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology 2004; 39: 197203.
  • 8
    Hui J M, Hodge A, Farrell G C, Kench J G, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 4654.
  • 9
    Xu A, Wang Y, Keshaw H, Xu L Y, Lam K S L, Cooper G J S. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver disease in mice. J Clin Invest 2003; 112: 91100.
  • 10
    Grove J, Daly A K, Brown A, St J M, Bassendine M F, James O F W, Day C P. The Rsa polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics 1998; 8: 33542.
  • 11
    Becker U, Gronbaek M, Johansen D, Sorensen T I A. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 2002; 35: 86875.
  • 12
    Rotily M, Durbec J P, Berthezene P, Sarles H. Diet and alcohol in liver cirrhosis: a case–control study. Eur J Clin Nutr 1990; 44: 595603.
  • 13
    Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput J C. Excess weight is a risk factor for alcoholic liver disease. Hepatology 1997; 25: 10811.
  • 14
    Raynard B, Balian A, Fallick D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35: 6358.
  • 15
    Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37: 90916.
  • 16
    Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38: 152939.
  • 17
    Wigg A J, Roberts-Thomson I C, Dymock R B, McCarthy P J, Grose R H, Cummins A G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 20611.
  • 18
    Hrubec Z, Omenn G S. Evidence for genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. Alcohol Clin Exp Res 1981; 5: 20715.
  • 19
    Stinson F S, Grant B F, Dufour M C. The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res 2001; 25: 11817.
  • 20
    Caetano R, Clark C L. Trends among alcohol related problems among whites, blacks, and Hispanics: 1984–1995. Alcohol Clin Exp Res 1998; 22: 5348.
  • 21
    Struben V M D, Hespenheide E E, Caldwell S H. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000; 108: 913.
  • 22
    Willner I R, Waters B, Patil S R, Reuben A, Morelli J, Reily C A. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 295761.
  • 23
    Browning J D, Kumar K S, Saboorian M H, Thiele D L. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99: 2928.
    Direct Link:
  • 24
    Caldwell S H, Harris D M, Patrie J T, Hespenheide E E. Is NASH underdiagnosed among African Americans? Am J Gastroenterol 2002; 97: 1496500.
    Direct Link:
  • 25
    Daly A K Day C P. Candidate gene case–control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001; 52: 48999.
  • 26
    Enomoto N, Yamashina S, Schemmer P, et al. Estriol sensitizes rat Kupffer cells via gut-derived endotoxin. Am J Physiol 1999; 277: G6717.
  • 27
    Day C P, James O F W. Hepatic steatosis – innocent bystander or guilty party? Hepatology 1998; 27: 14636.
  • 28
    Bernard S, Touzet S, Personne I, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000; 43: 9959.
  • 29
    Day C P, Leathart J B, Daly A K. Genetic evidence that fatty liver is involved in the pathogenesis of advanced alcoholic liver disease. J Hepatol 2002; 36 (Suppl. 1): 16.
  • 30
    Chao Y-C, Young T H, Tang H-S, Hsu C T. Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in chinese patients. Hepatology 1997; 25: 1127.
  • 31
    Chao Y C, Wang L S, Hsieh T Y, Chu C W, Chang F Y, Chu H C. Chinese alcoholic patients with esophageal cancer are genetically different from alcoholics with acute pancreatitis and liver cirrhosis. Am J Gastroenterol 2000; 95: 295864.
    Direct Link:
  • 32
    Tanaka F, Shiratori Y, Yokosuka O, Imazeki F, Tsukada Y, Omata M. High incidence of ADH2*1/ALDH2*1 gene among Japanese alcohol dependents and patients with alcoholic liver disease. Hepatology 1996; 23: 2349.
  • 33
    Osier M, Patstis A J, Kidd J R, et al. Linkage disequilibrium at the ADH2 and ADH3 loci and risk of alcoholism. Am J Hum Genet 1999; 64: 114757.
  • 34
    Borràs E, Coutelle C, Rosell A, et al. Genetic polymorphism of alcohol dehydrogenase in Europeans: the ADH2*2 allele decreases the risk for alcoholism and is associated with ADH3*1. Hepatology 2000; 31: 9849.
  • 35
    Grove J, Daly A K, Burt A D, et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 1998; 43: 2626.
  • 36
    Degoul F, Sutton A, Mansouri A, et al. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology 2001; 120: 146874.
  • 37
    Stewart S F, Leathart J B, Chen Y, et al. The valine–alanine manganese superoxide dismutase polymorphism is not associated with increased oxidative stress or susceptibility to advanced alcoholic liver disease. Hepatology 2002; 36: 135560.
  • 38
    Sanyal A J, Campbell-Sargent C, Mirshahi F, et al. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 118392.
  • 39
    Miele L, Grieco A, Armuzzi A, et al. Hepatic mitochondrial beta-oxidation in patients with non-alcoholic steatohepatitis assessed by 13C-octanoate breath test. Am J Gastroenterol 2003; 98: 22356.
    Direct Link:
  • 40
    Fan C-Y, Pan J, Usuda N, Yeldandi A V, Rao M S, Reddy J K. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 1998; 273: 1563945.
  • 41
    Merriman R B, Aouizerat B E, Molloy M J, Kane J P, Bacon B, Bass N M. A genetic mutation in the peroxisome proloiferator-activated receptor alpha gene in patients with non-alcoholic steatohepatitis. Hepatology 2001; 34: 441A.
  • 42
    Berger J, Moller D E. The mechanism of action of PPARs. Ann Rev Med 2002; 53: 40935.
  • 43
    Sapone A, Peters J M, Sakai S, et al. The human peroxisome proliferator-activated receptor α gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 2000; 10: 3213.
  • 44
    Ip E, Farrell G C, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 12332.
  • 45
    Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 128895.
  • 46
    George D K, Goldwurm S, Macdonald G A, et al. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 3118.
  • 47
    Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations and insulin resistance ro fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 17987.
  • 48
    Saksena S, Daly A K, Leathart J B, Day C P. Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2003; 38 (Suppl. 2): 47.
  • 49
    Baldini M, Lohman I C, Halonen M, Erickson R P, Holt P G, Martinez F D. A polymorphism in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20: 97683.
  • 50
    Järveläinen H A, Orpana A, Perola M, Savolainen V T, Karhunen P J, Lindros K O. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001; 33: 114853.
  • 51
    Leathart J B, Day C P, Daly A K. No association between functional SNPs in the endotoxin receptors CD14 and TLR4 and alcoholic liver disease (ALD): is endotoxin important in the pathogenesis of ALD in humans? Hepatology 2001; 34: 459A.
  • 52
    Arbour N C, Lorenz E, Schutte B C, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 18791.
  • 53
    Day C P. CD14 promoter polymorphism associated with risk of NASH. J Hepatol 2002; 36 (Suppl. 1): 21.
  • 54
    Grove J, Daly A K, Bassendine M F, Day C P. Association of a tumor necrosis factor polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26: 1436.
  • 55
    Valenti L, Fracanzani A L, Dongiovanni P, et al. Tumour necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 27280.
  • 56
    Pastor I J, Javier Laso F, Romero A, Gonzalez-Sarmiento G. −238 G/A polymorphism of tumour necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol Clin Exp Res 2005; 29: 192831.
  • 57
    Grove J, Daly A K, Bassendine M F, Gilvarry E, Day C P. Polymorphism associated with low interleukin-10 production is a risk factor for associated alcoholic liver disease. Gut 2000; 46: 5405.
  • 58
    Vidali M, Stewart S F, Rolla R, et al. Genetic and epigenetic factors in auto-immune reactions towards cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003; 37: 4109.
  • 59
    Waterhouse P, Marengere L E M, Mittrucker H W, Mak T W. CTLA-4, a negative regulator of T-lymphocyte activation. Immunol Rev 1999; 153: 183207.
  • 60
    Ueda H, Howson J M, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 50611.
  • 61
    Valenti L, De Feo T, Fracanzani A L, et al. Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. Alcohol Alcohol 2004; 39: 27680.
  • 62
    Dixon J B, Bhathal P S, Jonsson J R, Dixon A F, Powell E E, O'Brien P E. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 2003; 39: 96770.